(Q44477698)

3 December 2017

title

Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated (English)

1 reference

3 December 2017

0 references

8

1 reference

3 December 2017

Fabrizio Vincenzi

1

1 reference

3 December 2017

Carmen Corciulo

2

1 reference

3 December 2017

Martina Targa

3

1 reference

3 December 2017

Stefania Merighi

4

1 reference

3 December 2017

Stefania Gessi

5

1 reference

3 December 2017

Ilaria Casetta

6

1 reference

3 December 2017

Mauro Gentile

7

1 reference

3 December 2017

Pier Andrea Borea

9

1 reference

3 December 2017

Katia Varani

10

1 reference

3 December 2017

language of work or name

English

0 references

publication date

3 June 2013

1 reference

European Journal of Immunology

3 December 2017

published in

1 reference

3 December 2017

volume

43

1 reference

3 December 2017

issue

8

1 reference

3 December 2017

page(s)

2206-2216

1 reference

New and emerging disease modifying therapies for multiple sclerosis

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Multiple sclerosis: the role of cytokines in pathogenesis and in therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

The blood–brain barrier, chemokines and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Biologic therapies: lessons from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Current and emerging therapies in multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Adenosine receptors in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Modulation of innate immunity by adenosine receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Methylxanthines, inflammation, and cancer: fundamental mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Adenosine receptor targeting in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A2A receptors in inflammation and injury: lessons learned from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A molecular trio in relapse and remission in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Immune therapy of multiple sclerosis--future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Additive effect of prostaglandin E2 and adenosine in mouse experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Immunopathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Lethal multiple sclerosis relapse after natalizumab withdrawal

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201343314

7 January 2021

Identifiers

DOI

10.1002/EJI.201343314

1 reference

3 December 2017

1 reference